Jubilant Pharmova reports USFDA Warning Letter for Montreal contract manufacturing site
Jubilant Pharmova · Pharmaceuticals & Biotechnology
Key highlights
- USFDA issued a Warning Letter after inspection at Jubilant HollisterStier General Partnership facility in Kirkland, Montreal, Oct 20-Nov 3, 2025
- JHSGP is owned by subsidiaries of Jubilant Pharma Limited, itself a subsidiary of Jubilant Pharmova Limited
- JHSGP operations continue under enhanced controls while corrective and preventive actions are underway as of May 28, 2026
Why it's rated notable: A USFDA Warning Letter is an adverse regulatory action for the Montreal contract manufacturing facility, but the filing states no monetary amount and says current operations continue under enhanced controls, so the level is medium.
Original filing
USFDA Inspection Update - Contract Manufacturing Facility At Montreal, Canada
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Jubilant Pharmova
- Fundraise / allotmentNotableJubilant Pharmova Allots ₹800 Crore Non-Convertible Debentures on Nov 5, 2026
- Fundraise / allotmentNotableJubilant Pharmova allots ₹800 crore NCDs via private placement on Nov 5, 2026
- Fundraise / allotmentNotableJubilant Pharmova approves issuance of up to ₹800 crore NCDs on private placement
- Order winNotable· Adverse for the businessJubilant Pharmova receives USFDA approval for Line 3 at Spokane facility
Other order win filings this fortnight
- HLE Glascoat subsidiary Kinam Engineering secures $42-48M international order
- SpectraA Technology Solutions receives ₹21 crore domestic order for brewery project
- Ashoka Buildcon receives LoA for NHAI expressway project worth ₹865.90 crore
- L&T bags significant order from Noida Metro for Aqua Line Extension
- South West Pinnacle Exploration H1 FY27 revenue up 16% to Rs. 1194 Mn, PAT up 23%
- SEAMEC Limited awarded USD 26.14 million subsea installation contract by L&T
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.